Journal
CELL HOST & MICROBE
Volume 22, Issue 2, Pages 193-206Publisher
CELL PRESS
DOI: 10.1016/j.chom.2017.07.013
Keywords
-
Categories
Funding
- NIH [R01 AI127828, R01 AI114816, U19 AI109711, U19 AI117905, HHSN272201400024C]
- Moderna
- Sanofi
- Inovio
- Medimmune
- Profectus
- Arbutus
- Avatar
Ask authors/readers for more resources
Antibodies are the principal immune effectors that mediate protection against reinfection following viral infection or vaccination. Robust techniques for human mAb isolation have been developed in the last decade. The study of human mAbs isolated from subjects with prior immunity has become a mainstay for rational structure-based, next-generation vaccine development. The plethora of detailed molecular and genetic studies coupling the structure of antigen-antibody complexes with their antiviral function has begun to reveal common principles of critical interactions on which we can build better vaccines and therapeutic antibodies. This review outlines the approaches to isolating and studying human antiviral mAbs and discusses the common principles underlying the basis for their activity. This review also examines progress toward the goal of achieving a comprehensive understanding of the chemical and physical basis for molecular recognition of viral surface proteins in order to build predictive molecular models that can be used for vaccine design.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available